CompletedPhase 2NCT00309959
ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer
Studying Adenocarcinoma of the cervix uteri
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Gynecologic Oncology Group
- Principal Investigator
- David AlbertsGynecologic Oncology Group
- Intervention
- Paclitaxel Albumin-Stabilized Nanoparticle Formulation(drug)
- Enrollment
- 37 enrolled
- Eligibility
- FEMALE
- Timeline
- 2006
Study locations (26)
- University of Colorado Cancer Center - Anschutz Cancer Pavilion, Aurora, Colorado, United States
- Rush University Medical Center, Chicago, Illinois, United States
- Carle Clinic-Urbana Main, Urbana, Illinois, United States
- Iowa Methodist Medical Center, Des Moines, Iowa, United States
- Iowa Oncology Research Association CCOP, Des Moines, Iowa, United States
- Medical Oncology and Hematology Associates-Des Moines, Des Moines, Iowa, United States
- Medical Oncology and Hematology Associates-Laurel, Des Moines, Iowa, United States
- Mercy Medical Center - Des Moines, Des Moines, Iowa, United States
- Iowa Lutheran Hospital, Des Moines, Iowa, United States
- Mercy Hospital Springfield, Springfield, Missouri, United States
- Women's Cancer Center of Nevada, Las Vegas, Nevada, United States
- Cooper Hospital University Medical Center, Camden, New Jersey, United States
- Fox Chase Cancer Center at Virtua Memorial Hospital of Burlington County, Mount Holly, New Jersey, United States
- Virtua West Jersey Hospital Voorhees, Voorhees Township, New Jersey, United States
- Women's Cancer Care Associates LLC, Albany, New York, United States
- +11 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00309959 on ClinicalTrials.govOther trials for Adenocarcinoma of the cervix uteri
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07276360Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in UgandaUganda Cancer Institute
- RECRUITINGPHASE1NCT07454642AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid TumorsAvacta Life Sciences Ltd
- RECRUITINGPHASE3NCT07061977Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical CancerNational Cancer Institute (NCI)
- RECRUITINGNCT07359586Laryngopharyngeal Injury After Endotracheal Intubation Under General AnesthesiaZhejiang University
- RECRUITINGPHASE1NCT07020117A Study of [225Ac]Ac-AKY-1189 in Patients With Solid TumorsAktis Oncology, Inc.
- RECRUITINGPHASE2NCT06654011IN10018 With Nab-Paclitaxel and Cadonilimab for Metastatic or Recurrent Gastric-Type Cervical Adenocarcinoma: Phase 2 TrialUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT07153952RT for Adenocarcinoma/Adenosquamous CarcinomaPeking Union Medical College Hospital
- RECRUITINGNCT06733740Ultrasound-guided Thermal Ablation for Papillary Thyroid CarcinomaChinese PLA General Hospital